期刊
CANCER CELL
卷 26, 期 5, 页码 605-622出版社
CELL PRESS
DOI: 10.1016/j.ccell.2014.10.006
关键词
-
资金
- Enlight
- Ophthotech
- SynDevRx
- NIH [P01CA080124, R01CA163815]
- Proton Beam/Federal Share Program
- Department of Defense Breast Cancer Innovator Award
- National Foundation for Cancer Research
Ten antiangiogenic drugs targeting VEGF or its receptors are approved for cancer treatment. However, these agents, intended to block tumors' blood supply, may cause hypoxia, which may fuel tumor progression and treatment resistance. Emerging clinical data suggest that patients whose tumor perfusion or oxygenation increases in response to these agents may actually survive longer. Hence, strategies aimed at alleviating tumor hypoxia while improving perfusion may enhance the outcome of radiotherapy, chemotherapy, and immunotherapy. Here I summarize lessons learned from preclinical and clinical studies over the past decade and propose strategies for improving antiangiogenic therapy outcomes for malignant and nonmalignant diseases.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据